Prognostic factors and genes associated with endometrial cancer based on gene expression profiling by bioinformatics analysis

Archives of Gynecology and Obstetrics

Volumn 293, Issue 6, 2016, Pages 1287-1295

  Zhang, Ying ^a,b   Zhang, Wei ^a,b   Li, Xinglan ^a,b   Li, Dapeng ^a   Zhang, Xiaoling ^a   Yin, Yajie ^a,b   Deng, Xiangyun ^a,b   Sheng, Xiugui ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b UNIVERSITY OF JINAN   (China)

Author keywords

Endometrial cancer; Gene expression profile; Molecular mechanism; Prognostic factors

Indexed keywords

GLUCOSE TRANSPORTER 4; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FOS; KI 67 ANTIGEN; SLC2A4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BIOINFORMATICS; BODY MASS; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CCL20 GENE; CCNA2 GENE; CDK1 GENE; CELL CYCLE; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CANCER; FEMALE; FOS GENE; FOSB GENE; GENE; GENE EXPRESSION PROFILING; GENE MAPPING; GENETIC ASSOCIATION; GENETIC DATABASE; GENETIC VARIABILITY; GENOME; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; JUN GENE; LTF GENE; MAJOR CLINICAL STUDY; MELK GENE; MYOMETRIUM; PEG3 GENE; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RRM2 GENE; S100A8 GENE; SFRP4 GENE; SIGNAL TRANSDUCTION; TRH GENE; TUMOR INVASION; UPREGULATION; VERY ELDERLY; WIF1 GENE; BIOLOGY; ENDOMETRIUM TUMOR; EVALUATION STUDY; FACTUAL DATABASE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; MICROARRAY ANALYSIS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CELL CYCLE; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GLUCOSE TRANSPORTER TYPE 4; HUMANS; KI-67 ANTIGEN; MICROARRAY ANALYSIS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN INTERACTION MAPS; UP-REGULATION;

EID: 84944615334     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-015-3886-8     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29
2. Greven KM, Randall ME, Lanciano RM, Corn B, Case D (1993) Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. Cancer 71:3697–3702
3. Wolfson AH, Sightler SE, Markoe AM, Schwade JG, Averette HE, Ganjei P, Hilsenbeck SG (1992) The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol 45:142–146
4. Doll A, Abal M, Rigau M et al (2008) Novel molecular profiles of endometrial cancer—new light through old windows. J Steroid Biochem Mol Biol 108:221–229
5. Lax S, Kurman R (1996) A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 81:228–232
6. Kurose K, Zhou X-P, Araki T, Cannistra SA, Maher ER, Eng C (2001) Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158:2097–2106
7. Bansal N, Yendluri V, Wenham RM (2009) The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16:8
8. Lax SF, Kendall B, Tashiro H, Slebos RJ, Ellenson LH (2000) The frequency of p53, k-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma. Cancer 88:814–824
9. Liu F-S (2007) Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol 46:26–32
10. Byron SA, Gartside MG, Wellens CL et al (2008) Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res 68:6902–6907
11. Barrett T, Edgar R (2006) Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Methods Enzymol 411:352–369
12. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185–193
13. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article3
14. Aoki-Kinoshita KF, Kanehisa M (2007) Gene annotation and pathway mapping in KEGG. Comparative genomics. Springer, Berlin, pp 71–91
15. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA (2003) DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4:P3
16. Franceschini A, Szklarczyk D, Frankild S et al (2013) STRING v9. 1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41:D808–D815
17. Kohl M, Wiese S, Warscheid B (2011) Cytoscape: software for visualization and analysis of biological networks. Data mining in proteomics. Springer, Berlin, pp 291–303
18. Bader GD, Hogue CW (2003) An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 4:2
19. Frei KA, Kinkel K, BonéL HM, Lu Y, Zaloudek C, Hricak H (2000) Prediction of deep myometrial invasion in patients with endometrial cancer: clinical utility of contrast-enhanced MR imaging—a meta-analysis and Bayesian analysis 1. Radiology 216:444–449
20. Kinkel K, Kaji Y, Yu KK, Segal MR, Lu Y, Powell CB, Hricak H (1999) Radiologic staging in patients with endometrial cancer: a meta-analysis 1. Radiology 212:711–718
21. Koyama T, Tamai K, Togashi K (2007) Staging of carcinoma of the uterine cervix and endometrium. Eur Radiol 17:2009–2019
22. Nicholson RI, Gee JMW, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37:9–15
23. Fine B, Valente P, Feinstein G, Dey T (2000) VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Gynecol Oncol 76:33–39
24. Turpeenniemi-Hujanen T (2005) Gelatinases (MMP-2 and-9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87:287–297
25. Terakawa N, Kanamori Y, Yoshida S (2003) Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 10:203–208
26. Hamilton C, Cheung M, Osann K et al (2006) Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94:642–646
27. Petridou E, Belechri M, Dessypris N, Koukoulomatis P, Diakomanolis E, Spanos E, Trichopoulos D (2001) Leptin and body mass index in relation to endometrial cancer risk. Ann Nutr Metab 46:147–151
28. Lindemann K, Vatten L, Ellstrøm-Engh M, Eskild A (2008) Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer 98:1582–1585
29. Furberg AS, Thune I (2003) Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer 104:669–676
30. Friberg E, Orsini N, Mantzoros C, Wolk A (2007) Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50:1365–1374
31. Maatela J, Aromaa A, Salmi T, Pohja M, Vuento M, Grönroos M (1994) The risk of endometrial cancer in diabetic and hypertensive patients: a nationwide record-linkage study in Finland. Ann Chir Gynaecol Suppl 208:20–24
32. Bidus MA, Risinger JI, Chandramouli GV et al (2006) Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray. Clin Cancer Res 12:83–88
33. Hu X, Moscinski L (2011) Cdc2: a monopotent or pluripotent CDK? Cell Prolif 44:205–211
34. Dorée M, Hunt T (2002) From Cdc2 to Cdk1: when did the cell cycle kinase join its cyclin partner? J Cell Sci 115:2461–2464
35. Gong Q-F, Liu E-H, Xin R, Huang X, Gao N (2011) 2ME and 2OHE2 exhibit growth inhibitory effects and cell cycle arrest at G2/M in RL95-2 human endometrial cancer cells through activation of p53 and Chk1. Mol Cell Biochem 352:221–230
36. Sherr CJ (1994) G1 phase progression: cycling on cue. Cell 79:551–555
37. Kyushima N, Watanabe J, Hata H, Jobo T, Kameya T, Kuramoto H (2002) Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol 128:307–312
38. Vesely PW, Staber PB, Hoefler G, Kenner L (2009) Translational regulation mechanisms of AP-1 proteins. Mut Res 682:7–12
39. Salmi A, mmälä M, Rutanen EM (1996) Proto-oncogenes c-jun and c-fos are down-regulated in human endometrium during pregnancy: relationship to oestrogen receptor status. Mol Hum Reprod 2:979–984
40. Salmi A, Carpen O, Rutanen E (1998) The association between c-fos and c-jun expression and estrogen and progesterone receptors is lost in human endometrial cancer. Tumour Biol 20:202–211
41. Yokoyama Y, Sagara M, Sato S, Saito Y (1998) Value of glutathione S-transferase π and the oncogene products c-Jun, c-Fos, cH-Ras, and c-Myc as a Prognostic indicator in endometrial carcinomas. Gynecol Oncol 68:280–287